BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study

BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after

Targeted Therapy vs. Immunotherapy in Oncology: Advancements and Comparisons Since 2022

Targeted Therapy vs. Immunotherapy in Oncology: Advancements and Comparisons Since 2022 Abstract This paper analyzes the recent developments in targeted therapy and immunotherapy for cancer treatment, focusing on advancements made since 2022. It compares these two approaches by examining their mechanisms, effectiveness, and potential applications across

BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study